로그인
회원가입
Korean
Korean
English
Chinese
Japanese
Home
Introduction
Contact us
People
PI
Members
Research
Projects
Lab Facility
Publications
Papers
Books
Patents
Photo gallery
Photo gallery
Board
Projet update
Recruiting
Journal club
Home
People
Research
Publications
Photo gallery
Board
Home
Introduction
Contact us
People
PI
Members
Research
Projects
Lab Facility
Publications
Papers
Books
Patents
Photo gallery
Photo gallery
Board
Projet update
Recruiting
Journal club
MOON LAB SNS 바로가기
트위터
페이스북
네이버블로그
MOON LAB
홈페이지 바로가기
MOON LAB
Moon lab pursues development of novel therapeutics for breast, ovary, and prostate cancer
Journal club 글답변
이름
필수
비밀번호
필수
분류
선택하세요
Journal Club
Projet update
HTML
제목
필수
웹에디터 시작
> > > Title: Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor-positive breast cancers, highlighting new therapeutic modalities > Pancholi et al, Oncogene 2020; 39: 4781–4797 > > Abstract: > Combination of CDK4/6 inhibitors and endocrine therapy improves clinical outcome in advanced oestrogen receptor (ER)-positive breast cancer, however, relapse is inevitable. Here, we show in model systems that other than loss of RB1 few gene copy number (CN) alterations are associated with irreversible-resistance to endocrine therapy and subsequent secondary resistance to palbociclib. Resistance to palbociclib occurred as a result of tumour cell re-wiring leading to increased expression of EGFR, MAPK, CDK4, CDK2, CDK7, CCNE1 and CCNE2. Resistance altered the ER genome wide-binding pattern, leading to decreased expression of ‘classical’ oestrogen-regulated genes and was accompanied by reduced sensitivity to fulvestrant and tamoxifen. Persistent CDK4 blockade decreased phosphorylation of tuberous sclerosis complex 2 (TSC2) enhancing EGFR signalling, leading to the re-wiring of ER. Kinome-knockdown confirmed dependency on ERBBsignalling and G2/M–checkpoint proteins such as WEE1, together with the cell cycle master regulator, CDK7. Noteworthy, sensitivity to CDK7 inhibition was associated with loss of ER and RB1 CN. Overall, we show that resistance to CDK4/6 inhibitors is dependent on kinase re-wiring and the redeployment of signalling cascades previously associated with endocrine resistance and highlights new therapeutic networks that can be exploited upon relapse after CDK4/6 inhibition > >
웹 에디터 끝
첨부파일
파일추가
파일삭제
자동등록방지
숫자음성듣기
새로고침
자동등록방지 숫자를 순서대로 입력하세요.
작성완료
취소
전화걸기
문자상담
PL
MEMBERS